TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of HPV Vaccination on Women Aged 25 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* resident in Florence~* invited for the first time to the cervical cancer screening in Florence~* aged 25 years~Exclusion Criteria:~-

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- no HPV vaccine (Type: NO_INTERVENTION): No delivery of HPV vaccine
- HPV vaccine (Cervarix®, GlaxoSmithKline) (Type: EXPERIMENTAL): Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cell and Islet Co-transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic pancreatitis patients who undergo TP-IAT.~* \>18 years of age.~* Patients with BMI from 18.5 to 30.~* Renal function: \>90mls/min/1.73m squared~* Normal INR/PT/PTT values for MUSC clinical laboratory standards~* Diabetes free before surgery (fasting blood glucose\<125mg/dl).~* No prior pancreatic surgery with the exception of transduodenal sphincteroplasty or Whipple/Beger procedure.~* Patients with normal liver function as measured by serum levels of aminotransferase including alanine aminotransferase (ALT), and aspartate aminotransferase (AST), and total bilirubin levels.~Exclusion Criteria:~* Patients whose Hemoglobin, Hematocrit, and Platelet count are above or below normal values for MUSC clinical laboratory standards.~* Patients who has hematological malignancy.~* Patients who are under immunosuppression.~* Patients with marked calcification disease on CT scan.~* Patients with severe fibrosis and atrophy on pancreas MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Patients will receive standard islet transplantation.
- autologous mesenchymal stromal cell (Type: EXPERIMENTAL): Patients will receive MSCs together with standard islet transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of dementia of the Alzheimer's type, mixed dementia, or vascular dementia, as classified by the Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV)~* a score of 4 or more on the Functional Assessment Staging (FAST), a diagnostic tool for determining the stage of dementia~* a score of 23 or lower on the Mini-Mental State Examination (MMSE), a clinical measure used to evaluate cognition~* a BEHAVE-AD total score of at least 8, and a BEHAVE-AD global rating of at least 1~* residence in a psychiatric hospital, nursing home, or other long-term care facility for at least 1 month.~Exclusion Criteria:~* Patients with untreated, reversible causes of dementia~* with general medical or neurological conditions in which cognition is diminished (for example, untreated vitamin deficiency, severe liver or kidney malfunctions, brain tumor, etc.)~* with dementia related to HIV infection (human immunodeficiency virus)~* with a substance-induced persisting dementia~* with psychiatric disorders that could account for the behavior disturbances, such as schizophrenia.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Member of the Army on active duty status~* Personal access to Internet~* Anticipated stable assignment to installation for at least 2 months~* Stable dosing for ≥3 months, if receiving psychotropic medications~* Prior to enrollment, offered PTSD treatment using A-level modality (as defined by U.S. Army Medical Command (MEDCOM) policy 14-094; 18 Dec 2014).~* PTSD Checklist - Civilian (PCL-C) score of 32 or greater at screening~* Acceptable clinically indicated preoperative laboratory studies, per standard site-specific protocols~Exclusion Criteria:~* Prior Stellate Ganglion Block (SGB)~* Allergy to amide local anesthetics (e.g., ropivacaine, bupivacaine)~* Pregnancy (evaluated by urine test pre-procedure)~* Current anticoagulant use~* History of a bleeding disorder~* Infection or mass at injection site~* Myocardial infarction within 6 months of procedure~* Phrenic or laryngeal nerve palsy (hoarseness)~* History of glaucoma~* History of schizophrenia, other psychotic disorder, bipolar disorder, or personality disorder (axis 2)~* Moderate or severe traumatic brain injury~* Symptoms of moderate to severe substance use disorder in past 30 days~* Suicidal ideation in the past 2 months, documented by the M.I.N.I.-Plus Suicidality Items~* Any ongoing other major life stressor or condition not listed here that the site Investigator believes clearly would place the participant at risk for injury or a poor outcome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stellate Ganglion Block (SGB) (Type: ACTIVE_COMPARATOR): 7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
- Sham Treatment (Type: SHAM_COMPARATOR): 1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is at least 18 years of age~* Level of severity of bilateral nasolabial fold wrinkles meeting severity criteria as per protocol~* Level of subject dissatisfaction with both nasolabial fold wrinkles as per protocol~* Ability to comply with the study requirements~* Negative pregnancy test (Females)~* Healthy post-auricular skin for biopsy~Exclusion Criteria:~* Excessive dermatochalasis of the treatment area~* Inability to lessen the nasolabial fold wrinkles by physically spreading the area apart~* Total area to be treated exceeds 20 cm in length~* Physical attributes which may prevent assessment or treatment as judged by the evaluator~* Use of an investigational product/procedure within 30 days prior to enrollment or plans for use during the study~* Previous treatment with the sponsor's product~* History of active autoimmune disease or organ transplantation~* Diagnosis of cancer, unless successfully treated or in remission (basal cell carcinoma is excluded)~* Active or chronic skin disease~* Known genetic disorders affecting fibroblasts or collagen~* Active systemic infection~* Requires chronic antibiotic or steroidal therapy~* Use of certain commercial products/procedures to the treatment area prior to study enrollment or plans for use during the study~* Use of systemic agents that increase bleeding or clotting, or disorders equated with these effects~* Known allergic reactions to agents used in preparation of treatment~* Excessive exposure to sun without adequate sun protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): None
- Control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC~* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens~* Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen or combined modality (e.g., chemoradiation) regimen with curative intent~* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Known active or untreated central nervous system (CNS) metastases~* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome~* History of autoimmune disease~* History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted~* Active hepatitis B or hepatitis C~* Prior treatment with docetaxel~* Prior treatment with cluster of differentiation 137 (CD137) agonists, anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA4), anti-programmed death-1 (anti-PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody (Type: EXPERIMENTAL): Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
- Docetaxel (Type: ACTIVE_COMPARATOR): Docetaxel 75 milligrams per meter square (mg/m\^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes mellitus (T2DM) for at least 6 months~* Have been treated with stable metformin dose for at least 3 months~* Have HbA1c ≥7.5% and ≤11.0% at study entry~* Have body mass index (BMI) ≥25 kilograms per meter squared (kg/m\^2)~Exclusion Criteria:~* Have type 1 diabetes mellitus~* Have used any glucagon-like peptide-1 receptor agonist (GLP-1 RA) or insulin, not including prior short term insulin use (≤14 days)~* Have been taking any other medicine for diabetes (other than metformin) during the last 3 months~* Have used in the last 3 months (or plan to use) prescription weight loss medications~* Have disorders associated with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss~* Current participation in or intent to begin during the study an organized diet and/or exercise weight reduction program (other than the lifestyle and dietary measures for diabetes)~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level \>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial~* Had chronic or acute pancreatitis any time prior to study entry~* Have had a heart attack or stroke in the past 2 months, or have heart failure that significantly limits their physical activity~* Estimated glomerular filtration rate (eGFR) \<30 milliliters/minute/1.73m\^2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as determined by the central laboratory at study entry and confirmed at lead-in~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2~* Have proliferative retinopathy or maculopathy requiring acute treatment according to the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulaglutide 1.5 mg (Type: ACTIVE_COMPARATOR): Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
- Dulaglutide 3 mg (Type: EXPERIMENTAL): Dulaglutide 3 mg administered SC once a week.
- Dulaglutide 4.5 mg (Type: EXPERIMENTAL): Dulaglutide 4.5 mg administered SC once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HD patients ≥ 18 years of age in a stable phase of CKD as judged by the investigator~* Patients must have been on HD \> 3 months~* Patients must have received at least one dose of iron sucrose treatment within the last 6 months~Exclusion Criteria:~* Diafer® contraindications~* Patient not able to give informed consent~* Significant disease not related to CKD and likely to impact study results as evaluated by investigator~* Inability to estimate retrospective baseline data~* Planned change of iron dosing protocol or routines around iron administration during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients~* Aged 18-65 who meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for Major Depressive Disorder (MDD)~* Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score of at least 22 at visits 1 and 2~* Have a Clinical Global Impressions of Severity Scale (CGI-S) score of at least 4 at visits 1 and 2~* Have a degree of understanding such that the patient can provide informed consent, complete protocol required assessments and communicate intelligibly with the investigator and study coordinator.~Exclusion Criteria:~* Patients judged clinically to be at serious suicidal risk in the opinion of the investigator~* Patients who have any prior history of bipolar disorder, psychosis, or schizophrenia~* Patients who have any current (within the past six months) DSM-IV-TR primary Axis I disorder other than MDD~* Patients with uncontrolled narrow-angle glaucoma~* Patients who have a serious medical illness that is in the opinion of the investigator not stabilized or is likely to require intervention, hospitalization, or use of an excluded medication during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
- B (Type: PLACEBO_COMPARATOR): placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must meet all of the following laboratory criteria:~  * HDL-C \<40 mg/dL for men and \<50 mg/dL for women.~ * LDL-C ≥130 mg/dL but \<250 mg/dL.~ * TG \<350 mg/dL.~ * Creatine phosphokinase (CPK) \< 3 x upper limit of normal (ULN).~ * Alanine aminotransferase (ALT); serum glutamic pyruvic transaminase \[SGPT\] and aspartate aminotransferase (AST); serum glutamic oxaloacetic transaminase \[SGOT\] \< 1.3 x ULN.~* Subjects must also be reasonably compliant with the Therapeutic Lifestyle Changes (TLC) diet during the 4 to 5 week Screening Period prior to randomization (and be willing to comply for the duration of the study).~Exclusion Criteria:~* Subjects who have a history of any important medical conditions or abnormalities (as specified in the protocol) that would preclude study inclusion

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of bullous or non bullous impetigo. The patient has a total affected area comprised between 1-100 cm2 with surrounding erythema not extending more than 2 cm from the edge of any affected area. In case of multiple affected areas the total area will be the sum of each affected area and will not exceed 100 cm2. Additionally for patients \< 12 years the total area will not exceed a maximum of 2% of the body surface area.~* Total Skin Infection Rating Scale (SIRS) score of at least 8, including pus/exudate score of at least 1~Exclusion Criteria:~* Has a bacterial infection, which in the opinion of the investigator, could not be appropriately treated by a topical antibiotic.~* Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary temperature over 37.2 °C (99.0 °F)

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ozenoxacin 1% cream (Type: EXPERIMENTAL): 1% cream
- ozenoxacin placebo (Type: PLACEBO_COMPARATOR): cream
- retapamulin 1% ointment (Type: ACTIVE_COMPARATOR): 1% ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete